Inflammatory markers in women with a recent history of gestational diabetes mellitus

Journal of Endocrinological Investigation

Volumn 28, Issue 1, 2005, Pages 34-38

  Di Benedetto, A ^a,b   Russo, G T ^a   Corrado, F ^a   Di Cesare, E ^a   Alessi, E ^a   Nicocia, G ^a   D'Anna, R ^a   Cucinotta, D ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Cardiovascular disease; CRP; Fibrinogen; Gestational diabetes; MCP 1 CCL2

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; MONOCYTE CHEMOTACTIC PROTEIN 1; BIOLOGICAL MARKER; CCL2 PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBRINOGEN BLOOD LEVEL; HOMEOSTASIS; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; ORAL GLUCOSE TOLERANCE TEST; PARITY; PREGNANCY DIABETES MELLITUS; PROTEIN BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; METABOLISM; PREGNANCY; WAIST HIP RATIO;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHEMOKINE CCL2; COHORT STUDIES; DIABETES, GESTATIONAL; FEMALE; FIBRINOGEN; GLUCOSE TOLERANCE TEST; HUMANS; INFLAMMATION; PREGNANCY; WAIST-HIP RATIO;

EID: 21344449052     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03345527     Document Type: Article

References (28)

1. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2002, 25: S5-S20.
2. Verma A, Boney CM, Tucker R, Vohr BR. Insulin resistance syndrome in women with prior history of gestational diabetes mellitus. J Endocrinol Metab 2002, 87: 3227-35.
3. Meyers-Seifer CH, Vohr BR. Lipid levels in former gestational diabetic mothers. Diabetes Care 1996, 19: 1351-6.
4. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004, 27: 813-23.
5. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and the risk of developing type 2 diabetes mellitus. JAMA 2001, 286: 327-34.
6. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342: 836-43.
7. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999, 353: 1649-52.
8. de Maat MP, Pietersma A, Kofflard M, Sluiter W, Kluft C. Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis 1996, 121: 185-91.
9. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin or leukocyte count with coronary heart disease: meta-analysis of prospective studies. JAMA 1998, 279: 1477-82.
10. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002, 51: 455-61.
11. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001, 103: 2531-8.
12. Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S. Significance of chemokines and elevated platelets in patients with diabetes. Clin Exp Immunol 2000, 121: 437-43.
13. Piemonti L, Calori G, Mercalli A, et al. Fasting plasma leptin, tumor necrosis factor-α receptor 2, and monocyte chemoattracting protein 1 concentration in a population of glucose-tolerant and glucose-intolerant women. Diabetes Care 2003, 26: 2883-9.
14. Wolf M, Sauk J, Shah A, et al. Inflammation and glucose intolerance. A prospective study of gestational diabetes mellitus. Diabetes Care 2004, 27: 21-7.
15. Wolf M, Sandler L, Hsu K, Vossen-Smirnakis K, Ecker JL, Thadhani R. First trimester C-reactive protein and subsequent gestational diabetes. Diabetes Care 2003, 26: 819-24.
16. Retnakaran R, Hanley AJ, Raif N, Connelly PW, Sermer M, Zinman B. C-reactive protein and gestational diabetes: the central role of maternal obesity. J Clin Endocrinol Metab 2003, 88: 3507-12.
17. Carpenter MW, Coustan DR. Criteria for screening for gestational diabetes. Am J Obstet Gynecol 1982, 144: 768-73.
18. Corrado F, Caputo F, Facciola G, Mancuso A. Gestational glucose intolerance in multiple pregnancy. Diabetes Care 2003, 26: 1646.
19. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15: 539-53.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412-9.
21. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998, 41: 1241-8.
22. Festa A, D'Agostino R Jr, Howard G, Mykanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102: 42-7.
23. Frohlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000, 23: 1835-9.
24. Landin K, Stigendal L, Eriksson E, et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 1990, 39: 1044-8.
25. Ghanim H, Garg R, Aljada A, et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001, 86: 1306-12.
26. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107: 499-511.
27. Yla-Herttuala S, Lipton BA, Rosenfeld ME, et al. Expression of monocyte chemoattractant protein 1 in macrophages-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci 1991, 88: 5252-6.
28. Fernandez-Real JM, Ricart W. Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thriftiness. Diabetologia 1999, 42: 1367-74.